Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells

Cytotherapy

Volumn 18, Issue 3, 2016, Pages 465-480

  Villa, Nancy Y ^a   Bais, Swarna ^a   Chan, Winnie M ^a   Meacham, Amy M ^a   Wise, Elizabeth ^a   Rahman, Masmudur M ^a   Moreb, Jan S ^a   Rosenau, Emma H ^a   Wingard, John R ^a   McFadden, Grant ^a   Cogle, Christopher R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

bone marrow; mobilized peripheral stem cell blood; myxoma virus; purging; virotherapy

Indexed keywords

CD34 ANTIGEN; ONCOLYTIC VIRUS;

ARTICLE; B LYMPHOCYTE; COLONY FORMATION; COLONY FORMING CELL; CONTROLLED STUDY; CRYOPRESERVATION; CULTURE MEDIUM; EX VIVO STUDY; FLOW CYTOMETRY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INCUBATION TIME; MONOCYTE; MYXOMA VIRUS; MYXOMA VIRUS INFECTION; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD STEM CELL; POXVIRUS INFECTION; PRIORITY JOURNAL; STEM CELL CULTURE; TEMPERATURE; VIROTHERAPY; ADULT; AUTOGRAFT; BONE MARROW; BONE MARROW CELL; CELL CULTURE; CELL CULTURE TECHNIQUE; CELL SEPARATION; CYTOLOGY; FEMALE; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; METABOLISM; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PHYSIOLOGY; PREVENTION AND CONTROL; PROCEDURES; STANDARDS; TRANSPLANTATION CONDITIONING; TUMOR RECURRENCE;

ADULT; ANTIGENS, CD34; AUTOGRAFTS; BONE MARROW; BONE MARROW CELLS; CELL CULTURE TECHNIQUES; CELL SEPARATION; CELLS, CULTURED; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MYXOMA VIRUS; NEOPLASM RECURRENCE, LOCAL; ONCOLYTIC VIROTHERAPY; TRANSPLANTATION CONDITIONING;

EID: 84964388850     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.12.007     Document Type: Article

References (17)

1. Gribben JG, Nadler LM. Bone marrow purging for autologous bone marrow transplantation. Leuk Lymphoma 1993;11(Suppl. 2):141-8.
2. Kvalheim G. Purging of autografts: Methods and clinical significance. Ann Med 1996;28(2):167-73.
3. Rahman MM, Madlambayan GJ, Cogle CR, McFadden G. Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev 2010;21(2-3):169-75.
4. Yang H, Eaves C, de Lima MLM, et al. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts. Bone Marrow Transplant 2006;37(6):575-82.
5. Vellenga E, van Putten W, Ossenkoppele GJ, et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood 2011;118(23):6037-42.
6. Bartee E, Chan WM, Moreb JS, Cogle CR, McFadden G. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood MarrowTransplant 2012;18(10): 1540-51.
7. Lendvai N, Cohen AD, Cho HJ. Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone MarrowTransplant 2015;50(6):770-80.
8. Bais S, Bartee E, Rahman MM, McFadden G, Cogle CR. Oncolytic virotherapy for hematological malignancies. Adv Virol 2012;2012:1-8.
9. Kim M, Madlambayan G, Rahman M, et al. Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia 2009;23:2313-17.
10. Kim M, Rahman MM, Cogle CR, McFadden G. Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. Biochem Biophys Res Commun 2015;462(4):283-7.
11. Fry LJ, Giner SQ, Gomez SG, et al. Avoiding room temperature storage and delayed cryopreservation provide better postthaw potency in hematopoietic progenitor cell grafts. Transfusion 2013;53(8):1834-42.
12. Johnston JB, Barrett JW, Chang W, et al. Role of the serinethreonine kinase PAK-1 in myxoma virus replication. J Virol 2003;77(10):5877-88.
13. Li Y, Jiang M, Xu C, et al. Granulocyte colony-stimulating factor-primed bone marrow: an excellent stem-cell source for transplantation in acute myelocytic leukemia and chronic myelocytic leukemia. Chin Med J 2015;128(1):20-4.
14. Liu J,Wennier S, Reinhard M, Roy E, MacNeill A, McFadden G. Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. J Virol 2009;83(11):5933-8.
15. Villa NY, Wasserfall CH, Meacham A, et al. Myxoma virus suppresses proliferation of activatedT lymphocytes yet permits oncolytic virus transfer to cancer cells. Blood 2015;125(24): 3778-88.
16. Bartee E, Meacham A, Wise E, Cogle CR, McFadden G. Virotherapy using myxoma virus prevents lethal graft-versushost disease following xeno-transplantation with primary human hematopoietic stem cells. PLoS ONE 2012;7(8): e43298.
17. Chan WM, Rahman MM, McFadden G. Oncolytic myxoma virus: the path to clinic. Vaccine 2013;31(39):4252-8.